The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
Open accessAbstract
Purpose: The prognosis of elderly patients with acute myeloid leukemia (AML) is still dismal even with intensive chemotherapy. In this trial, we compared the antileukemic activity of standard induction and consolidation therapy with or without the addition of the kinase inhibitor sorafenib in elderly patients with AML. Patients and Methods: All patients received standard cytarabine and daunorubicin induction (7+3 regimen) and up to two cycles of intermediate-dose cytarabine consolidation. Two hundred one patients were equally randomly assigned to receive either sorafenib or placebo between the chemotherapy cycles and subsequently for up to 1 year after the beginning of therapy. The primary objective was to test for an improvement in event-free survival (EFS). Overall survival (OS), complete remission (CR) rate, tolerability, and several predefined subgroup analyses were among the secondary objectives. Results: Age, sex, CR and early death (ED) probability, and prognostic factors were balanced between both study arms. Treatment in the sorafenib arm did not result in significant improvement in EFS or OS. This was also true for subgroup analyses, including the subgroup positive for FLT3 internal tandem duplications. Results of induction therapy were worse in the sorafenib arm, with higher treatment-related mortality and lower CR rates. More adverse effects occurred during induction therapy in the sorafenib arm, and patients in this arm received less consolidation chemotherapy as a result of higher induction toxicity. Conclusion: In conclusion, combination of standard induction and consolidation therapy with sorafenib in the schedule investigated in our trial is not beneficial for elderly patients with AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Self-citationIntensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Juliusson, G., Antunovic, P., Derolf, Å., Lehmann, S., Möllgård, L., Stockelberg, D., Tidefelt, U., Wahlin, A., & Höglund, M. (2009) · Blood · doi:10.1182/blood-2008-07-172007 · Cited by 987
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Löwenberg, B., Ossenkoppele, G. J., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901409 · Cited by 828
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., et al. (1999) · PubMed · doi:10.1182/blood.v93.9.3074 · Cited by 757
Bloomfield, C. D., Lawrence, D. D., Byrd, J. C., Carroll, A. J., Pettenati, M. J., Tantravahi, R. V., Patil, S., Davey, F. R., Berg, D. T., Schiffer, C. A., et al. (1998) · PubMed · Cited by 682
Burnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A. L., Hunter, A., Goldstone, A. H., & Wheatley, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4310 · Cited by 657
Stone, R. M., DeAngelo, D. J., Klimek, V., Galinsky, I., Estey, E., Nimer, S. D., Grandin, W., Lebwohl, D., Wang, Y., Cohen, P., et al. (2005) · Blood · doi:10.1182/blood-2004-03-0891 · Cited by 657
Zarrinkar, P. P., Gunawardane, R. N., Cramer, M. D., Gardner, M. F., Brigham, D., Belli, B., Karaman, M. W., Pratz, K. W., Pallares, G., Chao, Q., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222034 · Cited by 634
Smith, B. D., Levis, M., Beran, M., Giles, F., Kantarjian, H., Berg, K., Murphy, K. M., Dauses, T., Allebach, J., & Small, D. (2004) · Blood · doi:10.1182/blood-2003-11-3775 · Cited by 632
Fiedler, W., Serve, H., Döhner, H., Schwittay, M., Ottmann, O. G., O'Farrell, A.-M., Bello, C. L., Allred, R., Manning, W. C., Cherrington, J. M., et al. (2005) · Blood · doi:10.1182/blood-2004-05-1846 · Cited by 490
Self-citationFiedler, W., Graeven, U., Ergün, S., Verago, S., Kilic, N., Stockschläder, M., & Hossfeld, D. K. (1997) · Blood · doi:10.1182/blood.v89.6.1870 · Cited by 437
Levis, M., Ravandi, F., Wang, E. S., Baer, M. R., Perl, A., Coutre, S., Erba, H., Stuart, R. K., Baccarani, M., Cripe, L. D., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301796 · Cited by 398
Büchner, T., Urbanitz, D., Hiddemann, W., Rühl, H., Ludwig, W. D., Fischer, J., Aul, H. C., Vaupel, H. A., Kuse, R., & Zeile, G. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.12.1583 · Cited by 362
Ravandi, F., Cortes, J. E., Jones, D., Faderl, S., Garcia-Manero, G., Konopleva, M. Y., O'Brien, S., Estrov, Z., Borthakur, G., Thomas, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4888 · Cited by 356
Büchner, T., Berdel, W. E., Haferlach, C., Haferlach, T., Schnittger, S., Müller-Tidow, C., Braess, J., Spiekermann, K., Kienast, J., Staib, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4245 · Cited by 338
Self-citationMutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
Zhang, W., Konopleva, M., Shi, Y.-X., McQueen, T., Harris, D., Ling, X., Estrov, Z., Quintás-Cardama, A., Small, D., Cortes, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm328 · Cited by 338
Krug, U., Röllig, C., Koschmieder, A., Heinecke, A., Sauerland, M. C., Schaich, M., Thiede, C., Kramer, M., Braess, J., Spiekermann, K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62105-8 · Cited by 304
Self-citationRahmani, M., Davis, E. M., Bauer, C., Dent, P., & Grant, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506551200 · Cited by 288
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
Fiedler, W., Mesters, R., Tinnefeld, H., Loges, S., Staib, P., Dührsen, U., Flasshove, M., Ottmann, O. G., Jung, W., Cavalli, F., et al. (2003) · Blood · doi:10.1182/blood-2002-10-2998 · Cited by 262
Self-citationFLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Sato, T., Yang, X., Knapper, S., White, P., Smith, B. D., Galkin, S., Small, D., Burnett, A., & Levis, M. (2011) · Blood · doi:10.1182/blood-2010-01-266742 · Cited by 261
Ohtake, S., Miyawaki, S., Fujita, H., Kiyoi, H., Shinagawa, K., Usui, N., Okumura, H., Miyamura, K., Nakaseko, C., Miyazaki, Y., et al. (2011) · Blood · doi:10.1182/blood-2010-03-273243 · Cited by 258
Metzelder, S., Wang, Y., Wollmer, E., Wanzel, M., Teichler, S., Chaturvedi, A., Eilers, M., Enghofer, E., Neubauer, A., & Burchert, A. (2009) · Blood · doi:10.1182/blood-2009-03-208298 · Cited by 250
Self-citationFLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
Pratz, K. W., Sato, T., Murphy, K. M., Stine, A., Rajkhowa, T., & Levis, M. (2010) · Blood · doi:10.1182/blood-2009-09-242859 · Cited by 242
Burnett, A. K., Hills, R. K., Milligan, D. W., Goldstone, A. H., Prentice, A. G., McMullin, M., Duncombe, A. S., Gibson, B. E. S., & Wheatley, K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9088 · Cited by 230
Pautas, C., Merabet, F., Thomas, X., Raffoux, E., Gardin, C., Corm, S., Bourhis, J.-H., Reman, O., Turlure, P., Contentin, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2652 · Cited by 218
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells
Zheng, R., Levis, M., Piloto, O., Brown, P., Baldwin, B. R., Gorin, N. C., Beran, M., Zhu, Z., Ludwig, D., Hicklin, D., et al. (2004) · Blood · doi:10.1182/blood-2003-06-1969 · Cited by 205
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
Borthakur, G., Kantarjian, H., Ravandi, F., Zhang, W., Konopleva, M., Wright, J. J., Faderl, S., Verstovsek, S., Mathews, S., Andreeff, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.030452 · Cited by 202
Büchner, T., Berdel, W. E., Schoch, C., Haferlach, T., Serve, H. L., Kienast, J., Schnittger, S., Kern, W., Tchinda, J., Reichle, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5013 · Cited by 179
Self-citationAntitumor activity of sorafenib in FLT3-driven leukemic cells
Auclair, D., Miller, D., Yatsula, V, Pickett, W., Carter, C., Chang, Y., Zhang, X., Wilkie, D., Burd, A., Shi, H., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404508 · Cited by 171
Sorafenib: a clinical and pharmacologic review
Iyer, R., Fetterly, G., Lugade, A., & Thanavala, Y. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.496453 · Cited by 169
Burnett, A. K., Milligan, D. W., Goldstone, A. H., Prentice, A. G., McMullin, M., Dennis, M. W., Sellwood, E., Pallis, M., Russell, N. H., Hills, R. K., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07604.x · Cited by 139
Pietsch, T., Kyas, U., Steffens, U., Yakisan, E., Hadam, M. R., Ludwig, W., Zsebo, K. M., & Welte, K. (1992) · Blood · doi:10.1182/blood.v80.5.1199.1199 · Cited by 129
von Bubnoff, N. C. C., Engh, R. A., Åberg, E., Sänger, J., Peschel, C., & Duyster, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2923 · Cited by 104
Self-citationSignal Transduction of Oncogenic Flt3
Choudhary, C., Müller‐Tidow, C., Berdel, W. E., & Serve, H. L. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05090 · Cited by 98
Self-citationParmar, A., Marz, S., Rushton, S. N., Holzwarth, C., Lind, K., Käyser, S., Döhner, K., Peschel, C., Oostendorp, R. A. J., & Götze, K. S. S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4136 · Cited by 96
Crump, M., Hedley, D. W., Kamel‐Reid, S., Leber, B. F., Wells, R. W., Brandwein, J. M., Buckstein, R. J., Kassis, J., Minden, M. D., Matthews, J., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903585286 · Cited by 84
Hofmann, W.-K., Heil, G., Zander, C., Wiebe, S., Ottmann, O. G., Bergmann, L., Hoeffken, K., Fischer, J. T., Knuth, A. K., Kolbe, K., et al. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0889-0 · Cited by 57
Self-citationZhang, T., Ding, X., Wei, D., Cheng, P., Su, X., Liu, H., Wang, D., & Gao, H. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283350e26 · Cited by 57
Potential role of sorafenib in the treatment of acute myeloid leukemia
Mori, S., Cortes, J. E., Kantarjian, H. M., Zhang, W., Andreef, M., & Ravandi, F. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802510349 · Cited by 55
Tong, F. K., Chow, S., & Hedley, D. W. (2006) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20092 · Cited by 52
Further activation of FLT3 mutants by FLT3 ligand
Zheng, R., Bailey, E., Nguyen, B., Yang, X., Piloto, O., Levis, M. J., & Small, D. (2011) · Oncogene · doi:10.1038/onc.2011.110 · Cited by 51
Foss, B., Ulvestad, E., & Bruserud, Ø. (2001) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2001.0430a.x · Cited by 45
Sorafenib for the management of advanced renal cell carcinoma
Escudier, B. J. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.55 · Cited by 28
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
‘Acute myeloid leukemia: a comprehensive review and 2016 update’
De Kouchkovsky, I., & Abdul-Hay, M. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.50 · Cited by 1,317
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Daver, N., Schlenk, R. F., Russell, N. H., & Levis, M. J. (2019) · Leukemia · doi:10.1038/s41375-018-0357-9 · Cited by 1,075
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., Bhatt, V., Bixby, D., Blum, W., Coutre, S. E., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0116 · Cited by 654
Burchert, A., Bug, G., Fritz, L. V., Finke, J., Stelljes, M., Röllig, C., Wollmer, E., Wäsch, R., Bornhäuser, M., Berg, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03345 · Cited by 555
Self-citation
Metadata
- Authors
- Serve, H., Krug, U., Wagner, R., Sauerland, M. C., Heinecke, A., Brunnberg, U., Schaich, M., Ottmann, O., Duyster, J., Wandt, H., Fischer, T., Giagounidis, A., Neubauer, A., Reichle, A., Aulitzky, W., Noppeney, R., Blau, I., Kunzmann, V., Stuhlmann, R., Krämer, A., Kreuzer, K.-A., Brandts, C., Steffen, B., Thiede, C., Müller-Tidow, C., Ehninger, G., & Berdel, W. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-09-01
- Volume
- 31
- Issue
- 25
- Pages
- 3110-3118
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106533048
- Cited by
- 313
- References
- 46
- FWCI
- 24.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.